-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $32

Benzinga·03/30/2026 17:48:32
Listen to the news
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $42 to $32.